India’s radiotherapy device market is entering a high-growth phase, driven by a sharp rise in cancer cases, expanding healthcare infrastructure, and increased public investment in oncology care. Industry estimates indicate the market could more...
The Indian government has outlined a clear strategy to transform the country’s pharmaceutical sector from being the “Pharmacy of the World” — known for affordable generics — to a global leader in high-value innovations, especially biologic...
The C4 Therapeutics & Roche cancer deal has taken a major step forward as both companies expand their partnership in a move that could exceed USD 1 billion. The updated agreement strengthens their focus on developing new cancer treatments using...
India’s pharmaceutical industry is likely to see pressure on its earnings from the US market in the coming quarter, even though domestic growth remains strong, according to a report by Nuvama Institutional Equities.
Alkem Laboratories Ltd. today announced the launch of A to Z Daily, an everyday multivitamin supplement for adults, for providing holistic nutritional support to the body and mind.
Kiran Mazumdar-Shaw has raised concerns over India’s listing rules, saying the current system fails biotech startups in India. She urged to rethink IPO norms for Biotech startups.
Senores Pharmaceuticals has taken a major step forward in its global growth journey by announcing a strategic joint venture to expand its presence in the United States federal healthcare market. This move highlights the company’s ambition to stren...
UPSIDA & JNPA pact is set to reshape India’s pharma export landscape. The Uttar Pradesh State Industrial Development Authority (UPSIDA) partners with Jawaharlal Nehru Port Authority (JNPA) to position the Lalitpur Pharma Park as a global export hub.
Bayer simplifies access to Eylea 2mg in India, enabling early treatment for retinal diseases like Wet AMD and DME, improving patient access and reducing cost barriers.
Emcure Pharmaceuticals has sharply cut the price of its weight loss drug Poviztra across India, slashing costs by an average of 47% to make the semaglutide based treatment more affordable for patients.The reduced pricing takes effect from April 3,
.jpg)
.jpg)
, CDSCO.jpg)